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Abstract
Hip geometry is an important predictor of fracture. We performed a meta-analysis of GWAS 
studies in adults to identify genetic variants that are associated with proximal femur geometry 
phenotypes. We analyzed four phenotypes: (i) femoral neck length; (ii) neck-shaft angle; (iii) 
femoral neck width, and (iv) femoral neck section modulus, estimated from DXA scans using 
algorithms of hip structure analysis. In the Discovery stage, 10 cohort studies were included in the 
fixed-effect meta-analysis, with up to 18,719 men and women ages 16 to 93 years. Association 
analyses were performed with ~2.5 million polymorphisms under an additive model adjusted for 
age, body mass index, and height. Replication analyses of meta-GWAS significant loci (at adjusted 
genomewide significance [GWS], threshold p ≤ 2.6 × 10−8) were performed in seven additional 
cohorts in silico. We looked up SNPs associated in our analysis, for association with height, bone 
mineral density (BMD), and fracture. In meta-analysis (combined Discovery and Replication 
stages), GWS associations were found at 5p15 (IRX1 and ADAMTS16); 5q35 near FGFR4; at 
12p11 (in CCDC91); 11q13 (near LRP5 and PPP6R3 (rs7102273)). Several hip geometry signals 
overlapped with BMD, including LRP5 (chr. 11). Chr. 11 SNP rs7102273 was associated with 
any-type fracture (p = 7.5 × 10−5). We used bone transcriptome data and discovered several 
significant eQTLs, including rs7102273 and PPP6R3 expression (p = 0.0007), and rs6556301 
(intergenic, chr.5 near FGFR4) and PDLIM7 expression (p = 0.005). In conclusion, we found 
associations between several genes and hip geometry measures that explained 12% to 22% of 
heritability at different sites. The results provide a defined set of genes related to biological 
pathways relevant to BMD and etiology of bone fragility.
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Introduction
Osteoporosis and associated fractures are common world-wide. In the United States alone, a 
total of 340,000 hip fractures occur each year, and the number of hip fractures is predicted to 
more than triple worldwide from 1.66 million in 1990 to 6.26 million in 2050.(1) In older 
individuals, hip fractures are a source of increased mortality, morbidity, and healthcare 
expenses. They are associated with a more than twofold increase in the likelihood of 
mortality, a fourfold increase in the probability of requiring institutional care, and a twofold 
increase in entering low-income status 1 year postfracture as compared to patients who do 
not sustain hip fractures.(2) Hip fractures may be preventable in as many as 50% of cases 
through the use of the available pharmacotherapies,(3) but improvements in the identification 
of high-risk patients are necessary.(4,5)
The most often studied phenotype for genetic studies of osteoporosis is bone mineral density 
(BMD) as assessed by dual-energy X-ray absorptiometry (DXA) of the hip. BMD is a two-
dimensional measure and does not account for the cross-sectional distribution of bone mass 
in the femur. BMD is an imperfect predictor of hip fracture and increasing attention has 
focused on contribution of other factors to bone strength, such as hip geometry.(6,7) Indeed, 
hip geometry traits have been associated with fracture risk, independent of BMD in most,
(8–11)
 but not all, studies.(11) Like BMD, hip geometry traits have a strong genetic 
component with a heritability of 28% to 70%.(12) Although some candidate-gene association 
studies(13–15) and modest-size genomewide association studies (GWASs) have been 
performed,(16–18) a powerful large-scale GWAS meta-analysis is essential in order to provide 
a comprehensive picture of the genetic architecture of hip geometry and to determine if 
novel genetic pathways independent of (BMD) BMD influence hip geometry. Understanding 
the genetics of hip geometry provides the potential to identify additional genetic architecture 
of fracture risk above and beyond BMD. There is also a complex relationship between adult 
height, bone geometry, and fracture risk. The premise of this study is that geometry of the 
proximal femur influences its predilection to fracture and that genetic factors responsible for 
determining the geometric features of the proximal femur could be involved in hip fracture 
risk.
In this study we performed a GWAS discovery analysis of hip geometry indices measured by 
DXA-derived hip structural analysis conducted on a large sample of women and men of 
predominantly European ancestry from the cohorts of the Genetic Factors for Osteoporosis 
(GEFOS) consortium.(19) The model adjusted for covariates, including body mass index 
(BMI) and height, was tested. This was followed by replication of the top findings in seven 
additional independent human cohorts. In order to prioritize variants that were novel for hip 
geometry, we then determined whether the genomewide association findings had also been 
found in previous GWASs of BMD phenotypes, height, or fracture. Finally, we assessed the 
functional relevance of the identified loci for bone biology using information from relevant 
sources, including gene expression data on cellular or whole animal models, as well as 
transcriptome and experimental studies in skeletal biopsies from human donors.
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Methods
Study subjects and hip geometry phenotypes
The Discovery stage of this study utilized data from 10 cohort studies and totaled data from 
18,719 adult men and women for whom genomewide SNP data and relevant hip geometry 
phenotypes were available. These individuals were from populations across North America, 
Europe, and East Asia, members of the Genetic Factors for Osteoporosis (GEFOS) 
consortium (Supporting Table 1a). The GEFOS consortium is an international collaboration 
of investigators dedicated to the identification of genetic determinants of osteoporosis and 
fragility fracture.(20–22) Additional descriptive information about the participating cohorts is 
available in Supporting Table 1a. Supporting Figure 1 illustrates the general schematic 
representation of the present study design.
We sought in silico independent replication, using summary results from seven cohorts (n = 
8334 men and women) with genomewide SNP data that became available after the initial 
discovery meta-analysis was completed. Characteristics of the replication cohorts are 
summarized in Supporting Table 1b. All studies were approved by institutional ethics review 
committees at the relevant organizations and all participants provided written informed 
consent.
Hip geometry measures were derived from DXA scans using the Hip Structural Analysis 
(HSA)(23) algorithm or a software supplied by a DXA machine manufacturer (see 
Supporting Table 1a,b). In each cohort study the following hip geometry indices were 
measured: femoral neck length (FNL), neck-shaft angle (NSA), the narrowest width of the 
femoral neck (NNW), and its section modulus (NNZ).(12) Coefficients of variation for hip 
geometry traits were reported to range from 3.3% (NN outer diameter) to 9.1% (FNL).(24)
In each cohort, at the time of the DXA exam or on a visit preceding it, standing height was 
measured and BMI calculated (Supporting Table 1a,b).(25)
GWAS of bone phenotypes
Genotyping and imputation methods—All the cohorts were genotyped using 
commercially available Affymetrix (Affymetrix Inc., Santa Clara, CA, USA) or Illumina 
(Illumina Inc., San Diego, CA, USA) genotyping arrays (Supporting Table 2). Quality 
control was performed independently in each study according to standard manufacturer-
provided protocols and within study procedures. To facilitate meta-analysis, each group 
performed genotype imputation with IMPUTE(26) or MACH(27) software (see Supporting 
Table 2 for details) using genotypes from the HapMap Phase II release 22, NCBI build 36 
(CEU or CHB/JPT as appropriate [for Hong-Kong cohort]) as reference panels. More recent 
reference panels such as HRC42 were not available at the time of the analyses. Each 
imputation software provides an overall imputation quality score for each single-nucleotide 
polymorphism (SNP). Analysis of imputed genotypes used either the dosage information 
from MACH or the genotype probabilities from IMPUTE (Supporting Table 2). Before 
performing an analysis, poorly imputed and low-frequency or rare polymorphisms were 
excluded. Specifically the quality control filters applied for exclusions of SNPs were: 
imputation quality score <0.3 for MACH and <0.4 for IMPUTE, average minor allele 
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frequency (MAF) of <1% across studies, and SNPs missing from ≥50% of the cohorts 
contributing to each outcome (at the meta-analysis stage). After quality control, up to ~2.5 
million SNPs were available from each cohort for the Discovery meta-analysis.
Association analyses—In the Discovery phase, each cohort conducted analyses 
according to a standard prespecified analysis plan under an additive (ie, per allele count) 
genetic model. Phenotypes were defined as the sex-specific standardized residuals derived 
from linear regression of each outcome variable on age, age2, BMI, and height. The 
assumption of normality of residuals in the linear regression model was checked within each 
cohort for each phenotype and no deviations were reported. The SNP–phenotype 
associations in each study were adjusted for potential confounding by population 
substructure using principal components as appropriate; pedigree and twin-based studies 
additionally corrected for family structure (using the R Kinship2 package: https://cran.r-
project.org/web/packages/available_packages_by_name.html ). Sex-specific analyses were 
performed, except for the family-based cohorts, where combined-sex models were generated 
with additional adjustment for sex. Cohort-specific summary statistics (beta-coefficients, 
standard errors, and p values) were used for the meta-analysis of each outcome variable 
(standardized residuals of FNL, NSA, NNW, and NNZ) with the genomewide SNPs. The 
replication analyses used the same analytical procedures as the Discovery analyses (eg, 
using study-specific standardized residuals from the covariate-adjusted model, as outcomes).
Meta-analysis—Meta-analysis of the GWAS discovery results was conducted and tested 
independently in two collaborating centers (Broad Institute and Hebrew SeniorLife, both in 
Boston, MA, USA). Because of potential power limitations to detect sex-specific 
associations (n males = 5510, n females = 11,701, see Supporting Table 1), we performed 
sex-combined meta-analysis. A fixed effects, sample size–weighted meta-analysis (using 
METAL software) was conducted in the Discovery set. Double genomic correction to 
control for potential inflation of the test statistics was performed, in individual studies and in 
the meta-analysis. The genomewide level of statistical significance (GWS) after adjustment 
for multiple correlated traits (effective n = 1.92), was set at p ≤ 2.6 × 10−8 and the suggestive 
level of significance at p < 5 × 10−6. The quantile-quantile (QQ) plots were generated for 
each phenotype, by pruning association results at a linkage disequilibrium (LD) threshold of 
0.50 (calculated with SNAP(28) using 1000 Genomes(29) data). Regional plots were 
generated with LocusZoom with modifications,(30) using chromosome position coordinates 
as provided in GrCh37/hg19.
In silico Replication and Combined meta-analysis—Because the in silico 
replication was performed in cohorts with existing genomewide data (and not by de novo 
genotyping), all the region-wide SNPs in the LD (r2 threshold of 0.7) interval with a 
genomewide significantly associated SNP(s) for hip geometry were taken forward for 
replication. Meta-analysis of the replication results was conducted by three collaborating 
centers (Broad Institute, Hebrew SeniorLife, Boston, MA, USA; and Ioannina, Greece). A 
fixed-effects model was used for meta-analysis of studies in the replication set and also in 
the final combined analyses of the discovery and replication sets, for each phenotype. 
Replication was proclaimed for any SNP when in the combined (joint) meta-analysis, (i) 
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GWS threshold was achieved and (ii) combined analysis p value was lower than that in the 
Discovery.
In silico search for independent signals (conditional analyses, Discovery 
stage)—To identify secondary (independent) association signals in the regions containing 
SNPs that were genomewide significant, we performed region-wide association analyses 
conditioning on the most significant hip-geometry SNP within a 1 megabase (Mb) window 
of the SNP with the lowest p value in a given locus, by including the other SNPs as a 
covariate in the regression models.
In silico search for height-associated SNPs, BMD-associated SNPs, and any 
type of fracture GWAS (Discovery stage)—In order to test for independence between 
the hip geometry and adult height signals, we looked up SNPs at least suggestively 
associated (p < 5 × 10−6) in our Discovery analysis, in the dataset of SNPs associated with 
height in the Genetic Investigation of ANthropometric Traits (GIANT) Consortium meta-
analysis of 183,727 subjects.(25) Furthermore, in order to determine if our GWS SNPs for 
hip geometry phenotypes were co-localized with previously identified SNPs for BMD, we 
looked up nearby “BMD SNPs.”(31) To assess the potential relevance of discovered loci to 
fracture risk, we looked up hip-geometry SNP associations (SNPs that were at least 
suggestively associated in our discovery analysis with one of the four hip geometry 
phenotypes, adjusted for covariates) with fracture using a large study from the GEFOS 
consortium (37,857 cases and 227,116 controls).(32,33)
LD score regression: SNP heritability and genetic correlations
LD score regression was used to estimate the SNP heritability (h2) of the studied traits and 
to estimate the genetic correlation (rg) (i) between hip geometry phenotypes and (ii) between 
hip geometry phenotypes and 235 traits and diseases with publicly available summary 
GWAS data using LD Hub.(34) This tool is a centralized database of summary-level GWAS 
results for hundreds of diseases/traits, as well as a Web interface that automates the LD score 
regression analysis pipeline.(35) To correct for multiple testing the rg was deemed significant 
at α = 0.0002 (0.05/235, Bonferroni-corrected for 235 tests).
Bioinformatic annotations and functional validation
Annotation of SNPs used NCBI’s dbSNP build hg19.
Gene expression analysis in human bone
Global gene expression profiling was performed in transiliac bone biopsies obtained from 
postmenopausal white women from Oslo, as described.(36) This permitted us to calculate the 
correlation values between hip geometry SNPs (and their proxies) and the transcript levels of 
genes in the vicinity of the identified loci. In brief, the women undergoing bone biopsies (50 
to 86 years old) were free from diseases other than osteoporosis or receiving medication 
(past or present) possibly affecting bone remodeling or representing secondary causes of 
osteoporosis.(36,37) RNA was purified and analyzed using Affymetrix HG U133 2.0 plus 
arrays as described.(36) Bone total RNA was subjected to global transcript profiling using 
HG-U133 plus 2.0 microarrays (Affymetrix). These data are available at the European 
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Bioinformatics Institute (EMBL-EBI) ArrayExpress repository, ID: E-MEXP-1618 (http://
www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-1618/).(17,38) DXA scans from the bone 
donors were subjected to HSA. Filtered transcript levels from 80 bone biopsies were 
correlated with hip geometry data; results were adjusted for multiple testing using false-
discovery rate (FDR).
cis-Expression quantitative trait loci in human bone tissues
Genomewide genotyping in the sample of women from Oslo was performed by Affymetrix 
Genome-Wide Human SNP Array 6.0/Affymetrix Axiom Biobank array (1,000,000 and 
700,000 SNPs assessed, respectively).(37) We conducted cis-expression quantitative trait loci 
(cis-eQTLs) analysis within a 2-Mb flanking region (1 Mb upstream and 1 Mb downstream) 
of each of the replicated SNPs to evaluate whether they influence transcript levels of genes 
in human whole bone (using the same resource of iliac bone biopsies from 80 
postmenopausal women).(17,38)
Gene expression in primary murine osteoblasts and osteoclasts
Gene expression profiles (“Trajectories”, ie, increase or decrease within the days post-
differentiation) of candidate genes in close proximity to genomewide associated SNPs were 
examined in primary mouse osteoblasts undergoing differentiation. These data have been 
described in detail(39) and are publicly available from the Gene Expression Omnibus 
(GSE54461). For details, see the Supporting Methods.
We also mined publically-available osteoclast expression data (GEO Accession 
GSM1873361; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72846) for 
expression (presence/absence) of candidate genes during osteoclastogenesis.
Coexpression network from mouse cortical bone
We used a coexpression network constructed from mouse cortical bone expression profiles.
(40)
 By mapping mouse homologs of human genes located in GWAS regions associated with 
BMD, the network previously identified an Osteoblast Functional Module containing 33 
genes implicated by GWAS.(40) For the association with hip geometry phenotypes, the 
following algorithm was applied:
Step 1: Using plink2, we generated LD intervals based on LD data from 1000 
Genomes Phase I. The interval was defined by the upstream-most and 
downstream-most SNP in LD with the index SNP at an r2 threshold of 0.7, 
as described in Calabrese and colleagues.(40) This resulted in the file 
“plink.ld” that contains all the proxies for the index SNPs based on build 
hg19.
Step 2: To define the set of genes mapped to the intervals, we converted the hg19 
LD intervals defined in step one to hg38 intervals using the UCSC lift-over 
tool. A total of 12 unique genes were identified for the 5 (GWAS 
Discovery) regions.
Step 3: We then identified mouse homologs for all 12 unique human genes and 
mapped these onto the bone coexpression network.(40)
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Assay for transposase-accessible chromatin followed by sequencing epigenetic 
intersection analyses
We used two functional epigenomic datasets derived using the Assay for Transposase-
Accessible Chromatin followed by sequencing (ATAC-seq) on embryonic day (E) 15.5 
mouse proximal femora: (i) proximal femur (head+neck+proximal femur growth plate up to 
but not including the osseous diaphysis) ATAC-seq dataset, which consists of 24,804 called 
peaks (n = 2 biological replicates)(41) and (ii) proximal femoral head ATAC-seq dataset, 
which consists of 22,727 called peaks (three biological replicates, unpublished). ATAC-seq 
assays and computational pipelines were performed as described in Guo and colleagues.(42) 
For both types of samples, we used stringent ENCODE recommended IDR (irreproducible 
discovery rate) cutoff of 0.05. Raw sequencing fastq files and processed peak bed files were 
previously deposited on NCBI GEO (GSE100585).
To perform computational intersections of these ATAC-seq datasets with height-adjusted 
hip-geometry-associated loci, Mus musculus (mm10) peak calls were first lifted over to the 
UCSC Genome Browser human genome (hg19). Second, we focused on the top five 
significant loci (Table 1), and for each lead (index) SNP we used the Broad Institute 
HaploReg v.4.1 tool(43) to identify all hg19 variants with an r2 ≥ 0.4 in the European 1000 
Genomes Population dataset. This yielded 513 height adjusted hip geometry variants that 
could serve as linked, putatively causal variants. Third, we used BEDTools v2.18(44) and the 
UCSC Genome Table Browser tool(45) to identify any overlap (≥1 bp) of a height adjusted 
hip geometry variant and an ATAC-seq peak. Fourth, for loci showing intersections, we used 
Mouse Genome Informatics to identify expression patterns for nearby genes, when 
appropriate.
Results
Each participating study analyzed hip geometry phenotypes by GWAS using standard best 
practices (see Methods). A meta-analysis of the individual GWASs was performed first on 
the first set of studies with available GWAS results. The meta-analysis QQ plots did not 
provide evidence of genomic inflation of association test statistics (λ’s ranging from 1.01 to 
1.07, (Supporting Table 3). Results of SNP–phenotype associations (hip geometry 
phenotype, top associated SNPs, their MAF, and functional impact) are presented in Table 1. 
Thus, the discovery analysis identified five loci with genomewide significant associations, in 
IRX1/ADAMTS16 and near FGFR4, NSD1, and RAB24 (chr. 5), a gene-dense region 
(LRP5/PPP6R3/GAL) on chr. 11, CCDC91 (chr. 12), and RUNX1 (chr. 21). The identified 
signals were either intronic or intergenic. Most of the loci were phenotype-specific. The 
chromosome region-wide association analyses with conditioning on the most significant 
SNP did not reveal secondary (independent) association signals.
The in silico replication was performed in the cohorts with existing GWAS, followed by the 
combined (joint) analysis of the Discovery and Replication stages. Thus, in the combined 
Discovery and Replication analysis, SNPs near IRX1/ADAMTS16 (chr. 5), a gene-dense 
region (LRP5/PPP6R3/GAL) on chr. 11, and CCDC91 (chr. 12) became GWS. SNP 
rs6556301 near FGFR4, NSD1, and RAB24 (chr. 5), although still meeting the GWS 
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threshold, became slightly less significant than that in the Discovery (p = 2.3 × 10−8 and 1.4 
× 10−8, respectively). SNPs in RUNX1 (chr. 21) did not replicate.
Some of the hip geometry–associated regions had previously been associated with DXA 
BMD (GEFOS Consortium, Table 2). Indeed, there were several signals overlapping with 
BMD at the suggestive level of significance (p < 5 × 10−6), mostly for narrow-neck section 
modulus phenotype: in/near LRP5 (chr. 11). We further compared the hip-geometry–
associated regions discovered by us with GWAS meta-analysis for height performed by the 
GIANT Consortium(25) (Table 3). Only rs11049605 in CCDC91 (chr. 12) was GWS-
associated with height.
We also looked up the SNPs that were suggestively (p < 5 × 10−6) associated with hip 
geometry in our Discovery analysis in the recent large GWAS of any type of fracture.(32) No 
SNP was nominally-significantly associated with fracture at p < 0.05 (Table 4).
Genetic correlations with hip geometry by LD score regression
LD score regression (Supporting Table 4) estimated that SNPs nominally associated with hip 
geometry phenotypes explained from 12.1 ± 2.7% heritability (NSA) and 12.9 ± 3.3% 
(FNL) to 17.5 ± 2.9% (NNZ) to 22.0 ± 3.2% of NN width. NNZ and NN width significantly 
correlated (0.369 ± 0.095, p < 0.001), whereas FNL and NSA negatively correlated (−0.526 
± 0.179, p < 0.01). We next determined the genetic correlations between hip geometry 
phenotypes and several traits and diseases (Supporting Table 5). Only other DXA-derived 
traits, including femoral, lumbar spine, and forearm BMD, demonstrated strong genetic 
correlation with NNZ (positive) or NNW (negative), at Bonferroni-corrected α threshold.
Gene expression analysis in human bone
We correlated hip geometry phenotypes with gene expression from human transiliac bone 
biopsies (Table 5). A total of 102 different transcripts were correlated with the various 
structural parameters at 10% FDR. Among Physiological System Development and Function 
categories the most significant were: “Connective Tissue Development and Function” (4.62 
× 10−2 to 3.12 × 10−4); “Embryonic Development” (4.63 × 10−2 to 3.12 × 10−4), “Organ 
Development” (4.63 × 10−2 to 3.12 × 10−4); “Organismal Development” (4.93 × 10−2 to 
3.12 × 10−4 ); “Skeletal and Muscular System Development and Function” (4.96 × 10−2 to 
3.12 × 10−4). Notably, several bone structure relevant subcategories (containing at least two 
genes) were identified within these categories, including: “Development of vertebral body” 
(CLEC3B), p = 3.12 × 10−4; “Differentiation of connective tissue cells” (IL1A, LRP8, 
MRPS18B, NIPBL, PIAS1, SOST, TOB1), p = 8.67 × 10−3; “Quantity of osteoclasts” 
(IL1A, SOST, TOB1), p = 1.43 × 10−2; “Ossification of bone” (NIPBL, SOST, TOB1), p = 
2.42 × 10−2.
cis-eQTLs in Human Bone Tissues
The results of the cis-eQTL obtained from whole-bone biopsies are shown in Table 6. For 
genomewide significant SNPs we found two significant eQTLs after multiple testing 
correction (adjusted for number of SNP-gene pairs by Bonferroni correction), namely 
rs7102273 (intergenic, chr. 11) and PPP6R3 (protein phosphatase 6 regulatory subunit 3) 
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expression (p = 0.0007), and rs6556301 (intergenic, chr. 5) and PDLIM7 (PDZ and LIM 
domain 7) expression (p = 0.005).
Primary murine cells
We tested whether mouse homologs of human genes were expressed in mouse calvarial 
osteoblasts and found that for some, the expression changed during cell differentiation. 
Table 7 presents a list of genes whose expression profiles (trajectories) underwent changes. 
Thus, Lrp5 expression increased with osteoblast differentiation; Rab24 expression slightly 
decreased; Irx1 expression increased and then reached a plateau at the late differentiation 
stage. Expression profiles for other genes were less obvious.
We also mined osteoclast expression data (GEO Accession GSM1873361; https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72846) and found evidence of 
expression of some of our genes of interest in control mice in mature osteoclasts. On chr. 5 
(proximal locus), Adamts16 expression, but not Irx1, was present during osteoclastogenesis; 
in distal locus on chr. 5, among the three genes of interest, expression of Rab24 and Nsd1 
was detected but reads mapping to Fgfr4, were not observed in mature osteoclasts 
suggesting a lack of expression of this gene in these cells. On chr. 11, notably Lrp5 and 
Ppp6r3 were expressed in osteoclasts whereas Gal was not.
Coexpression network from mouse cortical bone expression profiles
We previously used a network-based approach to nominate potentially causal genes at BMD 
GWAS associations.(40) In this work, Calabrese and colleagues(40) identified two modules 
from a bone coexpression network that were enriched for genes implicated by BMD GWAS. 
For the hip geometry GWAS results we determined if implicated genes were members of 
these two modules (referred to as modules 6 and 9). We hypothesized that genes implicated 
by hip geometry GWAS and members of modules 6/9 might play a role in the regulation of 
hip geometry and be strong candidates to underlie associations with hip geometry.
A total of 12 genes were identified for the five GWAS regions and all 12 had clear mouse 
homologs. Two (LRP5 and PPP6R3) of the 12 mouse genes belonged to either module 6 and 
or 9. Both of these modules have previously been shown to be enriched for genes with well-
known roles in osteoblast activity.
ATAC-seq epigenomic intersections in mice
We performed computational intersections between two ATAC-seq datasets derived from 
mouse embryonic proximal femora (see Methods) and 513 height-adjusted hip-geometry 
variants from five associated loci to identify putative regulatory variants influencing 
proximal femur geometry. Our intersections with a first dataset derived from all proximal 
femur tissues revealed five hip geometry variants from two loci that overlap with an ATAC-
seq peak (Supporting Table 6). At the IRX1/ADAMTS16 locus on chr. 5, four variants fEll 
within the same ATAC-seq peak, with rs6871994 in the strongest LD to lead variant (r2 = 
0.88) and associated with FNL. At the RUNX1 locus on chr. 21, rs8129061 is at r2 = 0.51 to 
the lead variant, resides within an ATAC-seq peak within a gene desert, and is associated 
with FNL. Intersections with a second dataset, focused specifically on the proximal femoral 
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head cartilage, did not yield any SNPs. All remaining loci (including FGFR4, NSD1, 
RAB24, LRP5, PPP6R3, GAL, and CCDC91) did not yield variant intersections with either 
dataset, although ATAC-seq peaks were identified in the vicinity of each gene (Supporting 
Fig. 2).
Discussion
This is the largest study to comprehensively assess genetic variants associated with proximal 
femur geometry using a GWAS approach with functional validation in human bone 
transcript profiles, cell, and animal data. Despite the contribution of bone geometry of the 
femur to fracture risk,(11) and the known heritability of hip geometry traits measured using 
HSA (28% to 70%(12)), there have been no large-scale GWASs for hip geometry. We 
assessed the evidence of association of the novel markers identified here, in large GWAS 
meta-analyses of height (183,727 participants(25)), DXA-derived lumbar spine (n ≅ 32,000) 
and femoral neck BMD (n ≅ 32,000),(20) as well as fracture (37,857 cases and 227,116 
controls from the GEFOS consortium).
Our GWAS findings identified several noteworthy genes. In the combined discovery and 
replication meta-analysis, significant associations were found for FNL at 5p15 where IRX1 
and ADAMTS16 are mapped (p = 2.4 × 10−8). In height-adjusted NNW, significant 
association was observed at 12p11 (p = 4.9 × 10−12) in the intron of CCDC91. Height-
adjusted NNZ was associated with variants at 11q13 near LRP5 and PPP6R3 (p = 4.3 × 
10−11), which are known genes for BMD. SNPs in FGFR4/NSD1/RAB24 (chr. 5) and in 
RUNX1 (chr. 21) did not replicate. It is of interest that FGFR4 interacts with FGF23, an 
inhibitor of mineralization; and RUNX1 is involved in hematopoiesis and osteogenesis.
Because stature is an important contributor to hip fracture, and because measures of hip 
geometry are dependent on an individual’s size, we performed a systematic study of the 
genetic associations of hip geometry with adjustment for height, in a sample of >27,000 
adults. Importantly, we performed GWAS of hip geometry with adjustment for height at a 
whole-genome scale, not only for the subset of SNPs previously shown to be associated with 
height (to prevent “collider bias”(45)). We did not adjust our hip geometry measures for areal 
BMD because these measures are both DXA-derived (therefore “collider bias”(45) might be 
expected). We also performed non–height-adjusted analysis (not shown here). The following 
chromosomal loci/genes were identified at suggestive-GWS levels: HHIP (chr. 4), ENPP2 
(on chr. 8), ASTN2/TMEM38B (chr. 9), near FAM10A4/DLEU2 (chr. 13), GDF5 and 
DDX27 (both on chr. 20). Not surprising, SNPs in most of these genes were also strongly 
associated with adult height. Of note, in our height-adjusted analysis, only rs11049605 in 
CCDC91 (chr. 12) was still GWS-associated with height, therefore indicating that 
adjustment for height dramatically reduced hip geometry associated signals, probably due to 
body-size contribution to the HG phenotypes.
Of note, one previous GWAS in 1000 European-descent Americans(16) found a common 
genetic variant, rs7430431 in the receptor transporting protein 3 (RTP3) gene, to be in strong 
association with the buckling ratio (p = 1.6 × 10−7), an index of bone structural instability, 
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and with femoral cortical thickness (p = 1.9 × 10−6). The RTP3 gene is located at 3p21.31. 
We were unable to confirm this signal in our much larger study.
We further looked for shared associations between our hip geometry phenotypes and bone 
fractures. SNP rs7102273 (intergenic, 11q13.2) was associated with fracture (p = 7.5 × 
10−5); the allele that was associated with higher NNZ, also corresponded to the lower risk of 
fracture. Of interest, this SNP is in LD (R2 = 0.96; Dˊ = 1) with another intronic variant, 
rs12272917, that was associated with skull BMD in Kemp and colleagues(46) study (the 
distance between the SNPs is ~122.2K). Both SNPs are in PPP6R3 (a.k.a. SAPS3) gene, 
whose Gene Ontology (GO) annotations include “protein phosphatase binding,” and related 
pathways are “Transport to the Golgi and subsequent modification” and “Vesicle-mediated 
transport.” It is still unclear how the gene may be influencing bone geometry. Some of our 
signals fall into known loci for other bone phenotypes. Apart from LRP5 and PPP6R3 (chr. 
11) there were no signals overlapping with BMD at the suggestive level of significance (p < 
5 × 10−6).
By correlating hip geometry phenotypes with gene expression from transiliac bone biopsies, 
we found gene transcripts falling into several functional categories. Among “Physiological 
System Development and Function” categories the most significant were “Connective Tissue 
Development and Function,” “Embryonic Development,” “Organ Development,” 
“Organismal Development,” and “Skeletal and Muscular System Development and 
Function.” Notably, several bone structure relevant subcategories (containing at least two 
genes) were identified within these categories, including: “Development of vertebral body,” 
“Differentiation of connective tissue cells,” “Quantity of osteoclasts,” and “Ossification of 
bone,” supporting the bone-structure role of the genes associated with hip geometry.
To further understand functional implications of our hip geometry signals via molecular and 
cellular mechanisms, we used the bone coexpression network from prior work of Calabrese 
and colleagues.(40) They found that mouse analogues of BMD GWAS genes were enriched 
for genes important to bone (mostly osteoblast) biology. By mapping mouse homologs of 
human genes located in GWAS regions onto murine dataset, they identified an Osteoblast 
Functional Module containing 33 genes implicated by GWAS. These genes are candidates 
for 30 of the 64 BMD GWAS regions discovered by GEFOS in European-descent persons.
(47)
 Most of the GO ontologies shared between these modules corresponded to cellular 
components, biological processes, and molecular functions pertinent to osteoblasts and 
ossification.(40,48) The top genes for hip geometry included PPP6R3 and LRP5, whose 
expression correlated with osteoblastic modules. We thus suggest that the identification of 
our GWAS top SNPs for hip geometry confirms they are excellent candidates for being 
potentially responsible for the signal in associated loci.
Given that greater than 95% of variants (ie, those with r2 > 0.4 to lead hip-geometry-
associated variants) fall within noncoding regions, they likely function to alter hip geometry 
through their effects on gene regulation. To refine the putative functional roles of hip 
geometry variants in this context and in the absence of inaccessible human developmental 
tissues, we performed computational intersections of all such variants with ATAC-seq 
datasets derived from embryonic mouse chondrocytes, at a stage when proximal femoral 
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morphology is initially determined. These analyses yielded two associated novel loci with 
five variants in strong to modest LD with the lead variant within an ATAC-seq peak. We 
detected variants in distant-acting enhancers at two loci associated with FNL (IRX1/
ADAMTS16 and RUNX1). Although mouse and/or human chondrocyte or bone phenotypes 
have only been reported for Runx1/RUNX1,(49) IRX1 has been shown to influence 
chondrocyte differentiation(50) and it (MGI(51)), along with Adamts16 (MGI(52)) and Runx1 
(MGI(53)) is expressed during mouse femoral development. Although follow-up experiments 
on variants in IRX1 could further demonstrate its role in hip geometry, its re-identification 
here bolsters our computational strategy to whittle down loci to fewer putatively causal 
variants.
We also mined two publicly available datasets, of primary mouse osteoblasts undergoing 
differentiation (GSE54461) and osteoclast expression data (GSM1873361). In mouse 
primary cells, among chr. 11 genes, Lrp5 (but not Ppp6r3) expression increased with 
osteoblast differentiation. For both Lrp5 and Ppp6r3, expression was present during 
osteoclastogenesis, whereas Gal was not expressed in either osteoblasts or osteoclasts. This 
evidence supports the role that LRP5, a well-known bone-active gene, plays in “pleiotropic” 
actions on most bone-related properties.
We then interrogated a unique dataset of global gene expression from transiliac bone 
biopsies obtained from 84 postmenopausal women.(36) In human whole bone biopsies, 
transcripts for LRP5 correlated with FNL of the biopsied persons (p < 0.05), whereas 
transcripts for RUNX1 correlated with their NNZ (p < 0.05). Finding the associations with 
LRP5 confirm earlier results of Wnt signaling system’s candidates associated with BMD and 
fracture risk.(36) Validation of our top genes detected in human bone samples by RT-PCR 
was carried out previously.(36,54)
Because most of these postmenopausal women with transiliac bone biopsies were 
genotyped, eQTLs were also available for our analysis. Thus, for subset of SNPs we found 
two eQTLs, still significant after applying multiple testing correction (by FDR), namely 
rs7102273 (intergenic, chr. 11) to associate with PPP6R3 expression (p = 0.0007), and 
rs6556301 (intergenic, chr. 5) with PDLIM7 expression (p = 0.005). PDLIM7 (PDZ and 
LIM Domain 7/ Enigma) is known to code for the LIM mineralization proteins (LMP), 
which have an important osteogenic role.(55) It seems that alteration of gene expression by 
the variants located in a regulatory region in the vicinity of PPP6R3, similar to PDLIM7, 
may affect bone geometry. We did not observe a link between the associated SNPs in the chr. 
11 region and LRP5 gene expression in human bones. The low expression level in whole 
bone and small sample size in human eQTL studies may limit the statistical power to detect 
cis-eQTLs.
We also estimated that SNPs associated with hip geometry phenotypes explained from 12.1 
± 2.7 heritability in NSA up to 22.0 ± 3.2 (NN width). NN section modulus and NN width 
significantly correlated (0.369 ± 0.095, p < 0.001), whereas FNL and NSA negatively 
correlated (−0.526 ± 0.179, p < 0.01). It is important to note that due to our relatively 
modest sample (n = 18,719), many more SNPs are expected to be uncovered through larger 
efforts, as follows from our experience with GWAS of other phenotypes, namely BMD, 
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height, and BMI, which will explain larger portion of heritability. Moreover, only singular 
signals (loci) generally reached GWS for each hip geometry trait: two for each FNL and 
NNW, one for NNZ, and none for NSA (Discovery). The impact of a single variant on a 
complex polygenic trait is usually small, and multiple variants with small effects, operating 
within a complex network, likely underlie hip geometry variance. Therefore, identification 
of a larger number of gene variants that play a role in bone architecture is necessary before 
real gains in predicting fracture risk can be achieved by using hip-geometry–associated 
variants. Statistical evidence (replication in independent cohorts) and biological evidence 
(from mammalian cells and human whole bone), although not always agree, are both 
indispensable for finding the true genetic loci.
The primary advantage of HSA-measured hip geometry is that bone geometry and areal 
BMD, both of which contribute to bone strength, are considered. This, however, makes our 
task of distinguishing between genetics of hip geometry per se, independent of BMD, 
challenging. It is important to emphasize that hip geometry is actually measured from the 
DXA image data, not estimated via the BMD. The algorithm of HSA was described in detail 
in Beck and Broy.(56) Of note, we found genetic correlations between some hip geometry 
phenotypes and DXA-derived BMD at femur, lumbar spine, and forearm. These genetic 
correlations were positive with NN-section modulus (bone strength measure) but negative 
with NN-width. The latter fully complies with the understanding that wider bones have 
larger cross-sectional area but not necessary higher density; this underlines the potential role 
of expansion of outer femoral neck diameter and cortical thinning that occurs with aging.(11) 
The oldest women had wider femoral necks containing less bone tissue, thinner cortices, less 
bending resistance, and significantly greater buckling ratios.(57)
This study has several limitations that need to be noted. GWAS studies were imputed to 
older imputation panels because the initial imputation began at the early stages of this 
project several years ago; at the present, newer and denser panels exist (1000Genomes, HRC 
and UK10K). More detailed exploration would need fine-mapping and sequencing of the 
loci prioritized here. Also, animal modeling experiments were considered beyond the scope 
of the present study. Given the biologic plausibility of our findings, further exploration is left 
to future studies.
In conclusion, our GWAS-based study provides indications that hip geometry measured 
using HSA may reveal novel molecular pathways influencing skeletal shape and impacting 
mechanical properties. Our findings also suggest that HAS-measured hip geometry might 
capture additional genetic determinants beyond those associated with hip BMD. These 
variants should be prioritized for future functional validation regarding their involvement in 
the regulation of bone strength and risk of hip fracture. At the current stage of genetics 
research, there are few instances where genetic association findings are directly used 
clinically. However, because hip geometry contributes to hip fracture risk,(2) discovery of 
genetic determinants of hip geometry may have utility in predicting fracture as methods to 
derive polygenic risk scores mature further.(3,4) Because hip geometry still evolves in early 
life and even beyond, the identification of genetic determinants of hip architecture could be 
used as potential diagnostic tools and drug targets to improve bone strength.
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